Cometriq
NICE recommends thyroid cancer drug trio for NHS use
February 20, 2018Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …
NICE provisionally rejects Ipsen’s kidney cancer drug Cabometyx
February 21, 2017Manufacturing and Production, Sales and Marketing Cometriq, NICE, ipsen
NICE has announced draft guidance for Ipsen’s cancer drug Cabometyx (cabozantinib), revealing it does not recommend the drug for use on …
Exelixis signs $200 million licensing deal for cancer drug
March 1, 2016Research and Development, Sales and Marketing Cancer, Cometriq, Exelixis, ipsen
Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
